Across TCGA pan-cancer cohorts, MMP17 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated MMP17 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MMP17 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MMP17 expression acts as an unfavorable survival marker.
HNSC, COAD, and LUAD are the cancer types where MMP17 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.